by Fred Dumais | Jun 13, 2024 | News Release
Record Q2-24 revenues of $14.1 million, up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million for Q2-23, up 48% Total Enerzair and Atectura prescriptions for the 12 months...
by Fred Dumais | Jun 13, 2024 | Communiqué de presse
Les changements apportés à l’unité commerciale respiratoire devraient générer des économies annuelles de plus de 5 millions de dollars Fait suite à des mesures de réduction des coûts de plus de 2 millions de dollars annoncées précédemment Les frais de...
by Fred Dumais | Jun 13, 2024 | News Release
Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exceeding $2 million Restructuring charges to be incurred in Q3-24 Cost reduction initiatives are aimed at improving margins,...
by Fred Dumais | Jun 4, 2024 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 4 juin 2024 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle divulguera ses résultats financiers et...
by Fred Dumais | Jun 4, 2024 | News Release
MONTREAL, QUEBEC , June 4, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2024 on...
